Selected article for: "activity relationship and acute respiratory syndrome sars"
Author: Liu, Wei; Zhu, He-Min; Niu, Guo-Jun; Shi, En-Zhi; Chen, Jie; Sun, Bo; Chen, Wei-Qiang; Zhou, Hong-Gang; Yang, Cheng
Title: Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
  • Cord-id: r0h2zhj2
  • Document date: 2014_1_1
    • ID: r0h2zhj2
    Snippet: The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitr
    Document: The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure–activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k(1) showed most potent inhibitory activity against 3CL(pro) (IC(50) = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs.

    Search related documents:
    Co phrase search for related documents
    • acid water and acute respiratory: 1, 2, 3, 4, 5
    • acid water and acute respiratory syndrome: 1, 2, 3, 4, 5
    • active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site catalytic dyad and acute respiratory: 1, 2, 3, 4
    • active site catalytic dyad and acute respiratory syndrome: 1, 2, 3
    • active site catalytic dyad pro and acute respiratory: 1
    • active site dock and acute respiratory: 1
    • active site dock and acute respiratory syndrome: 1
    • activity result and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activity result and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activity tendency and acute respiratory: 1, 2, 3
    • activity tendency and acute respiratory syndrome: 1, 2, 3
    • activity variation and acute respiratory: 1